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Alzheimer’s disease (AD) is the most common form of dementia affecting elderly people.
AD is a multifaceted pathology characterized by accumulation of extracellular neuritic
plaques, intracellular neurofibrillary tangles (NFTs) and neuronal loss mainly in the cortex
and hippocampus. AD etiology appears to be linked to a multitude of mechanisms
that have not been yet completely elucidated. For long time, it was considered that
insulin signaling has only peripheral actions but now it is widely accepted that insulin
has neuromodulatory actions in the brain. Insulin signaling is involved in numerous
brain functions including cognition and memory that are impaired in AD. Recent studies
suggest that AD may be linked to brain insulin resistance and patients with diabetes
have an increased risk of developing AD compared to healthy individuals. Indeed
insulin resistance, increased inflammation and impaired metabolism are key pathological
features of both AD and diabetes. However, the precise mechanisms involved in the
development of AD in patients with diabetes are not yet fully understood. In this review
we will discuss the role played by aberrant brain insulin signaling in AD. In detail, we will
focus on the role of insulin signaling in the deposition of neuritic plaques and intracellular
NFTs. Considering that insulin mitigates beta-amyloid deposition and phosphorylation
of tau, pharmacological strategies restoring brain insulin signaling, such as intranasal
delivery of insulin, could have significant therapeutic potential in AD treatment.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia. About 35.6 million people
worldwide are now suffering from AD, and disease prevalence is expected to affect 115 million
by 2050 (Wortmann, 2012). AD is a progressive, degenerative, and irreversible neurological
disorder that causes deterioration of memory, judgment, and reasoning in the elderly (Querfurth
and Laferla, 2010). Patients suffering from AD exhibit cognitive impairment, memory loss, and
behavioral changes (Querfurth and Laferla, 2010). The neurodegeneration in AD is characterized
by neuronal loss and synaptic injury (Dekosky and Scheff, 1990). The main pathological hallmarks
of AD are extracellular insoluble beta amyloid (Aβ) plaques (Selkoe, 1989) and intracellular
neurofibrillary tangles (NFTs). AD may be classified in two types based on genetic endowment.
The first type is inherited via an autosomal dominant pattern, i.e., familial AD, and the second
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type is sporadic AD. Familial AD displays early disease onset,
whereas sporadic AD cases mostly develop the disorder at an
older age (Cruts and Van Broeckhoven, 1998). Although AD
was discovered a century ago, the etiology of sporadic AD is
not well understood. Over decades, it was hypothesized that
neurodegeneration in AD is mainly caused by Aβ accumulation,
phosphorylated tau aggregation, and/or neuroinflammation.
However, recent human and preclinical studies have provided
convincing evidence that AD is a degenerative metabolic
disease, which is mediated by impairments in brain insulin
responsiveness, glucose utilization, and energy metabolism
leading to increased oxidative stress, inflammation, and
worsening of insulin resistance (Hoyer, 2002, 2004; Schubert
et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and
Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al.,
2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012;
Butterfield et al., 2014a,b; de La Monte, 2014).
The accumulating evidence that reduced glucose utilization
and deficient energy metabolism occur early in the course
of disease, suggests a role for impaired insulin signaling in
the pathogenesis of neurodegenerative diseases. In brain, the
insulin/insulin-like growth factor (IGF) signaling is important
for neuronal growth, synaptic maintenance and neuroprotection
(Stockhorst et al., 2004; Van Dam and Aleman, 2004). It is
now proposed that impairments in brain insulin/IGF signaling
is associated with increased accumulation of Aβ, phosphorylated
tau, reactive oxygen/nitrogen species, pro-inflammatory and
pro-apoptosis molecules (de La Monte et al., 2009; de La
Monte, 2012a,b, 2014). Both restoration of insulin responsiveness
and use of insulin therapy can lead to improved cognitive
performance. This review focuses on the recent progress in
our understanding of the neuronal insulin signaling in the
pathogenesis and progression of AD. The review will also discuss
therapeutic augmentation of brain insulin signaling by intranasal
insulin delivery as a promising treatment for AD.
Insulin Signaling in the Brain
The role of insulin in the brain has been little studied compared
with its role in peripheral tissue. However, there is evidence
that insulin has important functions in the brain including
metabolic, neurotrophic, neuromodulatory and neuroendocrine
actions. Recent studies have demonstrated that insulin and
insulin receptor (IR) are ubiquitously expressed in the brain as
in peripheral tissues (Schulingkamp et al., 2000; Van Der Heide
et al., 2006). Brain insulin levels can reach 10- to 100- fold greater
than in plasma, especially in hippocampus, hypothalamus,
cortex, olfactory bulb, substantia nigra and pituitary (Frolich
et al., 1998; Van Der Heide et al., 2006). IRs are abundantly
expressed in neurons and less abundantly in glia (Frolich
et al., 1998). Insulin is a hormone that has wide range of
functions. Insulin is important for cell growth and survival. In
the brain, insulin, IGFs and their receptors regulate dendritic
sprouting, neuronal stem cell activation, cell growth, repair,
synaptic maintenance and neuroprotection (Craft and Watson,
2004; Hoyer, 2004; Stockhorst et al., 2004; Van Dam and Aleman,
2004; Kleinridders et al., 2014). Insulin not only regulates glucose
and lipid metabolism in the brain, but also plays an important
role in learning and memory (Zhao et al., 2004b). Insulin is
actively transported across blood–brain-barrier (BBB) and it is
also produced locally in the brain (Banks et al., 2012). Similar to
insulin, IGF-1 is present also in rodent and human brain and can
cross BBB (Duarte et al., 2012).
IR and IGF receptor type-1 (IGF-1R) are tetrameric
glycoproteins that belong to the receptor tyrosine (Tyr)
kinase superfamily, composed of two α and two β subunits
(Schlessinger, 2000; Wada et al., 2005; Moloney et al., 2010;
Duarte et al., 2012). Two different types of IR have been reported:
neuron specific type (extensively expressed in neurons) and
peripheral-like type (with lower density in glia cells) (Moreira
et al., 2009). Due to structural and functional similarity, insulin
and IGF-1 can activate both IR and IGF-1R, however they exhibit
higher affinity to own receptors (<1 nM) (Conejo and Lorenzo,
2001). Once bound to their respective receptors, insulin or IGF-
1 promotes autophosphorylation of tyrosin residue, triggering
its intrinsic tyrosin activity and phosphorylating insulin receptor
substrate (IRS) docking protein at tyrosine residue (Duarte
et al., 2012). IRS-1 and IRS-2 are ubiquitously expressed and
are the primary mediators of insulin-dependent mitogenesis
and regulation of glucose metabolism in most cell types. IRS-
1 was the first substrate identified and represents the prototype
of the IRS family proteins, while IRS-2 was initially identified
as an alternative substrate for the IR in animals with targeted
disruption of the IRS-1 gene (Sesti et al., 2001). IRS is a critical
switch in the insulin-signaling pathway, and also interacts with
other receptor tyrosine kinases including IGF1/2, tropomyosin-
related kinase receptor B (TrkB) and ErbB. The phosphorylation
of IRS1 on tyrosine residues leads to the downstream activation of
Akt, the mammalian target of rapamycin (mTOR) and glycogen
synthase kinase 3 (GSK3), among other pathways; moreover,
the phosphorylation of IRS1 on multiple serine (Ser) residues
can inhibit IRS1 activity, leading to insulin resistance (Yarchoan
et al., 2014). Several reports suggested that insulin signaling is
altered in aging as well as in AD. Table 1 summarizes alteration
of insulin signaling components in aging as well as in the AD.
Figure 1 illustrates how aberrant insulin signaling is linked to
AD pathology and how it forms a vicious cycle, which results
in deterioration of learning and memory and neuronal loss. In
the following section we will discuss the evidence of relation
of insulin signaling deficiency with AD pathology and disease
progression.
Insulin Signaling and AD Pathology
Ample number of evidence suggested that alterations in
brain insulin metabolism could be one pathological factor for
neurodegenerative diseases including AD. In support of this
hypothesis, AD patients have shown reduced brain insulin
receptor sensitivity, hyperphosphorylation of insulin receptor
and downstream second messenger such as insulin receptor
substrate-1 (IRS-1) and attenuated insulin and insulin-like
growth factor receptor expression (Watson and Craft, 2003;
Rivera et al., 2005; Steen et al., 2005; Holscher and Li, 2010; Talbot
et al., 2012; de La Monte, 2012c; Freiherr et al., 2013). Moreover,
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TABLE 1 | Altered insulin signaling in normal aging and Alzheimer’s diseases.
Subjects/Tissue Components of insulin
signaling system
Observation References
AGING
Rats/hippocampus IGF-1
IGF-2
Unchanged [125I]IGF-I, [125I]IGF-II or [125I]insulin binding levels
in normal aging process
Dore et al., 1997
Human patients/plasma IGF-I ↓ plasma IGF-I levels with aging Mustafa et al.,
1999
Fisher 344 × brown Norway hybrid rats/plasma
and CSF
IGF-1
IGF-1R
IGFBP
↓ mRNA and protein levels in aged animals Ashpole et al.,
2015
Aged C57BL6 Mice/whole brain, serum and
CSF
IGF-1 ↓ IGF-1 levels in brain, CSF and serum in aged mice
↑ IGF-1R in aged mice hippocampus
↓IGF-1R/Akt/GSK3 signaling pathway
Muller et al., 2012
ALZHEIMER’S DISEASE
AD human patients/Hippocampus, cortex, and
cerebellum
IGF-II
Mannose -6-phosphate
receptor
Unchanged Kar et al., 2006
AD human patients/frontal, temporal, parietal,
and occipital cortex
Insulin
IR
c-peptide levels
- Strong insulin immunoreactivity in pyramidal neurons
compared to age-matched controls
- Unchanged insulin and c-peptide levels
- Increased IR density
- No significant difference in IGF-1binding
Frolich et al., 1998
AD human patients/frontal cortex,
hippocampus, hypothalamus
Insulin
IGF-1
IGF-2 receptor mRNA
↓ IR and IGF-1R mRNA in hippocampus and hypothalamus
↓ insulin and IGF-2 mRNA in hippocampus and hypothalamus
and IGF-1 in frontal cortex
↓ insulin, IGF-1, IR and IGF-1R-positive neurons in hippocampus
↓ IR and IGF-1R protein in hippocampus
↓ tyrosyl-phosphorylated IR, IGF-1R and IRS-1 in hippocampus,
cortex and hypothalamus
↓ IRS-2 protein in hippocampus
Impaired IRS-1 signaling in hippocampus and hypothalamus
(↓p85-associated IRS-1)
↓ pAkt and pGSK-3b
Steen et al., 2005
AD human patients/Plasma, serum IGF-1
IGFBPs
↑ total and unbound IGF-1 levels
↑ serum and CSF levels of IGF-1 and IGFBPs
Vardy et al., 2007;
Salehi et al., 2008
AD human patients/CSF Insulin ↓ insulin in mild AD patients
↓ insulin in MCI women
- Positive correlation of insulin with Aβ1−42 levels and cognitive
score
Gil-Bea et al.,
2010
AD human patients/Temporal cortex IGF-1R
IGFBP-2
Unaltered IR protein levels however altered its distribution in AD
neurons
↑ IGF-1R;↓IGFBP-2
↑ IGF-1R surrounding and within plaques and in astrocytes
↓ IRS-1and IRS-2 protein levels
↑ phosphoIRS-1 levels near NFTs
Moloney et al.,
2010
AD human brain tissue/
cynomolgus monkeys (i.c.v. injection of Aβ
oligomer/AβPP-PS1 Tg mice
IRS-1 ↑ IRS-1pSer636/639 levels in hippocampus
↑ IRS-1pSer636/639 levels were observed in neurons targeted
by Aβ
Bomfim et al.,
2012
AD human patients, triple transgenic mouse
model, Cultured rat hippocampus neurons (Aβ
oligomer insult)
IRS-1 ↑ active JNK and IRS-1pSer616 levels
Redistribution of IRS-1pSer616 expression from nucleus to
cytosol in AD human patients and 3×Tg-AD
↑ IRS-1pSer616 colocalized with NFTs
Aβ oligomer induced expression of IRS-1pSer616 in
hippocampal neurons culture
Ma et al., 2009
(Continued)
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TABLE 1 | Continued
Subjects/Tissue Components of insulin
signaling system
Observation References
AD human patients/cortex and hippocampus Insulin
IGF-1
IRS-1
- Unchanged basal levels of insulin and IGF-1 signaling
molecules
- Trend to increase IRS-1 levels in hippocampus
- ↓in responses to insulin signaling in the IR→IRS-1→PI3K
signaling pathway and greater→ in responses to IGF-1 in the
IGF-1R→IRS-2→PI3K signaling pathway in AD
- IRS-1 pS616 and IRS-1 pS636/639 correlated positively with
Aβ plaques and negatively associated with memory
Talbot et al., 2012
AD human patients/frontal cortex Insulin
IGF-1
IRS-2
↓ insulin, IGF-1 and IGF-2 receptor mRNA and polypeptide
mRNA in AD
↓ binding of 125 I labled insulin, IGF-1 and IGF-2
Rivera et al., 2005
Hippocampal and cortical neuronal cultures
S.D.
Rats (soluble Aβ oligomer insult)
IR Tyr phosphorylation Soluble Aβ oligomer inhibits IR activity (IR Tyr phosphorylation)
↑ Akt serine473 phosphorylation (Akt-pSer473)
Zhao et al., 2008
AD human patients/plasma IGF-1 ↓ plasma IGF-1 level in familial AD patients
carrying the swedish AβPP 670/671 mutation
Mustafa et al.,
1999
AD human patients/serum and CSF IGF-1
IGF-2
IGFBP
↑ IGF-2 in both AD serum and CSF
↑ IGF-1 in AD serum
↑ IGFBPs in the CSF of the AD patients
Tham et al., 1993
AD human patients/CSF and plasma Insulin ↓ CSF insulin and CSF-to-plasma insulin ratio
↑ plasma insulin
Craft et al., 1998
AD human patients/cortex Insulin signaling ↓ total and phosphorylated components of insulin-PI3K-Akt
signaling in AD
Liu et al., 2011
AD human patients/cortex and hippocampus IRS-1 ↑ IRS1-pS616, IRS1-pS312, Akt-pS473 in AD
Co-expression of IRS1-pS616 with pathological tau neurons
Yarchoan et al.,
2014
AD human patients/plasma Insulin ↑ plasma insulin after oral glucose tolerance test in AD patients
↑ CSF insulin levels
Fujisawa et al.,
1991
Tg2576 mice of AD IGF ↓ serum IGF levels Carro et al., 2002
IR, insulin receptor; IGF-1R, insulin growth factor receptor 1; IGF-2R, insulin growth factor receptor 2; IRS-1, insulin receptor substrate-1; IRS-1pSer636/639, IRS-1 phosphorylated at
serine residues 636/639; JNK, c-Jun N-terminal kinase; PI3K, phosphatidyl inositol 3-kinase; CSF, cerebrospinal fluid.
reduced CSF insulin levels have been observed in AD. However,
few studies have demonstrated either normal or increased CSF
insulin levels in AD patients (Freiherr et al., 2013). However, CNS
has hyper-insulinemia in AD is still controversial.
Neuritic (Amyloid Beta) Plaques
The amyloid plaques found in the brains of patients with AD
are mainly composed of Aβ, a peptide derived from a larger
molecule that is known as the amyloid precursor protein (AβPP).
AβPP is normally cleaved within its extracellular domain by a
protease known as “α-secretase,” and the processing releases a
large, soluble APP fragment (sAPPα) into the extracellular space
(Querfurth and Laferla, 2010). Because cleavage occurs within
the Aβ domain, α-secretase processing does not generate Aβ.
Aggregation prone and damaging Aβ originate from proteolysis
of the AβPP by the sequential enzymatic actions of beta-
site amyloid precursor protein–cleaving enzyme 1 (BACE-1), a
β-secretase, and γ-secretase (Querfurth and Laferla, 2010). Aβ
peptides are natural products of metabolism consisting of 36–43
amino acids. Monomers of Aβ40 are much more prevalent than
the aggregation-prone and damaging Aβ42 species. An imbalance
between production and clearance, and aggregation of peptides,
causes Aβ to accumulate, and this excess may be the initiating
factor in AD (Querfurth and Laferla, 2010).
Several lines of evidence suggested a link between energy
metabolism defects to functional alterations associated with
pathogenesis of AD. Inhibition of energy metabolism can alter
AβPP processing and induce amyloidogenic products (Gabuzda
et al., 1994). The relationship between insulin and Aβmetabolism
is receiving increasing attention. Recently, a direct link between
the Aβ metabolism and insulin pathways has been described in
neuronal cell lines (Solano et al., 2000; Gasparini et al., 2001).
Insulin treatment elevated sAPPα secretion in a concentration-
and tyrosin kinase-dependent manner in the neuronal cells and
also reduced the Aβ accumulation in neuronal cells (Solano
et al., 2000; Gasparini et al., 2001). It has been demonstrated
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FIGURE 1 | Aberrant brain insulin signaling in Alzheimer’s Disease
(AD). Schematic outline of neuronal insulin signaling in the normal brain (A)
and AD brain (B). Under physiological conditions, insulin binding to its
receptor triggers phosphorylation of insulin receptor substrate-1 (IRS-1). This
results in phosphoinositide 3-kinase (PI3K) activation and downstream cellular
responses that facilitate neuronal growth, neuronal survival, synaptic plasticity,
learning and memory, etc. Activation of the IR can result in both vasodilatation
and vasoconstriction and under physiological conditions there is a balance of
both processes to regulate the immediate metabolic requirements of various
tissues. In AD, accumulation of amyloid-β (Aβ) oligomers leads to increased
tumor necrosis factor-alpha (TNF-α) levels and activation of stress kinases
such as c-Jun N-terminal kinase (JNK) resulting in inhibitory serine
phosphorylation of IRS-1 (1). Aβ oligomers cause removal of IRs from the cell
surfacemediated by Casein Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent
Kinase II (CaMKII) and redistribute them to cell bodies (2). Insulin resistance
lowers the expression of Aβ-degrading insulin degrading enzyme (IDE) (3).
Lowered IDE expression further decreases the availability of IDE for Aβ
degradation. The reduction in brain insulin signaling increases GSK-3β activity
(4), which increases abnormal tau phosphorylation. Deficient insulin signaling
leads to impairment in nerve growth, synaptic plasticity, learning and memory,
etc. (5). Aberrant phosphorylation of IRS causes an imbalance in homeostatic
regulation of vascular function (6). This decreased production of NO may
results in decreased cerebral blood flow and increased pro-inflammatory
cytokines and reactive oxygen species production.
that insulin and IGFs can protect neurons from Aβ-induced
neurotoxicity in neuronal cultures (Mattson, 1997). Therefore,
sAPPα derived from insulin-mediated metabolism of AβPP
may function in modulation of neuronal excitability, synaptic
plasticity, neurite outgrowth, synaptogenesis, and cell survival
(Mattson, 1997). It has been recently shown that IGF-1 enhances
clearance of brain Aβ bymodulating transport and/or production
Aβ carriers at the blood–brain interface in the choroid plexus
(Ashpole et al., 2015). IGF-1 seems to increase Aβ clearance
by enhancing transport of Aβ carrier proteins such as albumin
and transthyretin into the brain (Carro et al., 2002). Under
physiological conditions insulin degrading enzyme (IDE) is
secreted at high levels from the microglial cells, and degrades
Aβ extracellularly (Qiu et al., 1998). In addition to insulin
degradation, IDE has been found to degrade Aβ in neuronal and
microglial cell cultures, and to eliminate neurotoxic effects of Aβ
(Qiu et al., 1998; Vekrellis et al., 2000; Sudoh et al., 2002). Insulin
can modulate the extracellular degradation of Aβ through insulin
degrading enzyme (IDE), which is involved in insulin catabolism
(Kurochkin and Goto, 1994; Authier et al., 1996; Qiu et al., 1998;
Farris et al., 2003). The expression of IDE is under control of
insulin levels. Insulin via phosphatidylinositol-3-kinase (PI3K)
pathway increases IDE protein levels (Zhao et al., 2004a). In line
with this, IDE knockout mice exhibited elevated levels of cerebral
Aβ (Farris et al., 2003). In contrary, overexpression of IDE in
the AβPP double transgenic mice decreased their brain Aβ levels,
and completely prevented Aβ plaque formation (Leissring et al.,
2003). Further support for this link was provided by the findings
that deficient insulin signaling (decreased PI3K subunit P85) was
correlated with reduced IDE in AD brains and in Tg2576 Swedish
AβPP transgenic mice (Zhao et al., 2004a). Aβ degrading activity
of IDE was shown to be lower in AD brains compared to controls
(Perez et al., 2000). On the other hand, Aβ oligomers cause rapid
and significant disruption of signaling by brain cell IRs.
It has been demonstrated that, acute treatment with Aβ
oligomer to hippocampus caused a rapid and substantial loss
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of neuronal surface IRs specifically on dendrites bound (Zhao
et al., 2008; de Felice et al., 2009). Aβ oligomer-treated neurons
showed elevated levels of IRs in their cell bodies, suggesting
redistribution of IRs (Figure 1). The rapid redistribution of
surface receptors rather than net receptor loss in short term
Aβ oligomer treatment was further supported by Western blots,
which showed no Aβ oligomer-induced changes in total IR levels
(Zhao et al., 2008). This leads to decreased responsiveness to
insulin, revealed by impaired insulin-induced receptor protein
tyrosine kinase activity in cultured neurons exposed to oligomers
(Zhao et al., 2008; de Felice et al., 2009). The Aβ oligomer-
induced redistribution of IRs is consistent with the reports
in which other synaptic proteins, such as NMDA receptors
subunits and EphB2 receptor tyrosin kinase, also showed
surface loss by soluble Aβ oligomers (Snyder et al., 2005;
Lacor et al., 2007). Although Aβ oligomer-induced removal of
NMDA receptors is mediated by α-7 nicotinic receptors, the
Aβ oligomers-induced loss of dendritic IRs dose not follow
similar mechanism (Snyder et al., 2005). Aβ oligomers are known
to cause internalization of NMDA receptors through Casein
Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent Kinase II
(CaMKII) (Chung et al., 2004). Therefore it was hypothesis that
Aβ oligomer-induce internalization of NMDA receptors and IRs
might share common mechanisms involving CK2 and CaMKII.
Consistent with this hypothesis De Felice et al showed that Aβ
oligomer caused major downregulation of membrane surface IRs
via mechanism sensitive to CK2 and CaMKII (de Felice et al.,
2009).
IRs play key roles in the important neurological processes
including learning and memory and tau phosphorylation. Thus,
Aβ oligomer-induced loss of membrane IRs might represent
an important early mechanism underlying memory impairment
and other pathological features of AD. Therefore, Aβ oligomers-
induced loss of IR receptors can lead to learning and memory
impairments and over tau phosphorylation. Further research
in this field revealed that Aβ oligomers-induced neuronal
oxidative stress. IR down-regulation and synaptic loss are
markedly decreased by insulin treatment (de Felice et al., 2009).
Neuroprotection by insulin requires IR tyrosin kinase activity,
which suggested that insulin through IR might downregulate
Aβ oligomer binding sites in the synapse instead of a simple
competition between Aβ oligomers and insulin for a common
binding site on the neuronal surface.
Inhibition of brain insulin signaling by streptozotocin,
a compound known to induce diabetes, treatment to rat
astrocytoma cells induced amyloidogenic protein expression as
evidenced by the increase in AβPP, BACE-1, and Aβ42 expression
(Rajasekar et al., 2014). Furthermore, it has been demonstrated
that Aβ oligomer-induces elevation in proinflammatory tumor
necrosis factor-alpha (TNF-α) levels and it triggers aberrant
activation of c-Jun N-terminal kinase (JNK) in neurons,
which ultimately leads to serine phosphorylation of IRS-1
(Bomfim et al., 2012). IRS-1 serine phosphorylation (IRS-1pSer)
blocks the downstream insulin signaling, which triggers, in
turn, peripheral insulin resistance (de Felice, 2013). Aberrant
insulin signaling accelerates plaque production in the brain
by enhancing the amyloidogenic processing of the AβPP
(Wang et al., 2010; Son et al., 2012), and also increases Aβ
aggregation through monosialotetrahexosylganglioside (GM1)
clustering and membrane signaling (Yamamoto et al., 2012).
Thus, Aβ oligomer-induced insulin resistance may create a
vicious cycle in which oligomers upregulate their own production
and aggregation by disrupting insulin physiological actions. Such
a mechanism could account in part for Aβ oligomer build up in
AD brains.
Neurofibrillary Tangles
Tau is a neuronal microtubule-associated protein found in
axons. Tau plays an important role in assembly and stability
of microtubules as well as in vesicle transport in neurons.
Tau, in its hyperphosphorylated form, is the major component
of paired helical filaments (PHFs), the building block of
neurofibrillary lesions in AD brain. Hyperphosphorylated tau
is insoluble, does not have affinity for microtubules, and self-
associates into paired helical filament structure (Querfurth
and Laferla, 2010). Abnormal hyperphosphorylation of tau
prompts an accumulation of NFTs in axons of neurons, can
impair normal axon transport, disrupt synaptic plasticity and
finally induce cell loss (Querfurth and Laferla, 2010; Bedse
et al., 2015). Evidence suggests that abnormal activation of
kinases like GSK-3β as well as caspases may be responsible
for hyperphosphorylation of tau (Churcher, 2006; Rohn, 2010).
IR activation, through phosphorylated IRS proteins, results
in activation of multiple signaling pathways including PI3K
and extracellular signal-regulated kinase (ERK) that directly
regulated various physiological processes (Figure 1) (Saltiel,
2001). Activation of PI3K→Akt cascade promotes neuronal
growth and survival (Rodgers and Theibert, 2002). Akt
inactivates GSK-3β, which inhibits tau phosphorylation (Zhao
et al., 2009; Perluigi et al., 2014). There are number of
evidence showing that insulin regulated tau phosphorylation
and increased rate of NFT development (Hong and Lee,
1997; Lesort and Johnson, 2000; Schubert et al., 2003; Cheng
et al., 2005; Freude et al., 2005). It has been shown that
insulin and IGF-1 regulate tau phosphorylation through the
inhibition of GSK-3β in cultural neurons. These effects of insulin
and IGF-1 are mediated through the inhibition of GSK-3β
via the PI3K-protein kinase B (PI3K-PKB) signaling pathway
(Hong and Lee, 1997). Moreover, peripheral hyperinsulinemia
promotes tau phosphorylation in vivo (Freude et al., 2005).
When IGF-1 and IRS-2 gene were deleted, tau phosphorylation
was dramatically increased in IGF-1 and IRS-2 knockout mice
(Schubert et al., 2003; Cheng et al., 2005). IGF-1 genetic
deletion specifically increased tau phosphorylation at two specific
residues, Ser-293 and Ser-202, both GSK-3β targeted sites (Cheng
et al., 2005). Inhibition of brain insulin signaling by intra
cerebroventricular administration of streptozotocin also induces
hyperphosphorylation of tau at multiple sites (Deng et al., 2009;
Chen et al., 2013). This treatment dramatically increased total
tau and hyperphosphorylated tau in the hippocampus of triple
transgenic AD (3×Tg-AD) mice (Chen et al., 2013, 2014a).
These results suggested that insulin and IGF-1 signaling normally
prevents tau hyperphosphorylation in the brain. As mentioned
earlier in the review, diabetes is characterized by insulin
Frontiers in Neuroscience | www.frontiersin.org 6 June 2015 | Volume 9 | Article 204
Bedse et al. Aberrant insulin signaling in Alzheimer’s disease
resistance, hyperinsulinemia and impaired insulin signaling. In
type 2 diabetes increased GSK-3β activity might lead to an
elevation of Aβ production (Phiel et al., 2003) and increased tau
phosphorylation (Freude et al., 2005; Sims-Robinson et al., 2010).
On the other hand, Aβ oligomer induced JNK activation leading
to phosphorylation and degradation of the adaptor protein IRS-1
(Ma et al., 2009). IRS deficiency contributes to insulin resistance
in diabetes. Significantly reduced IRS-1 and IRS-2 levels occur
in AD brain, accompanied by elevated cytosolic phosphor-IRS1
(Ser 312 and 316) (Ma et al., 2009; Bomfim et al., 2012; Talbot
et al., 2012; Yarchoan et al., 2014). Phosphorylation of IRS-1
(Ser 312 and 316) inhibits the regulation of insulin on GSK-3β
activity, which leads to further increase in hyperphosphorylation
of tau (Ma et al., 2009). The association of IRS1 abnormalities
and tau was further supported by double immunofluorescence
experiments demonstrating frequent co-expression of IRS1-
pS616 with tau lesions in neurons and dystrophic neuritis
(Yarchoan et al., 2014). The activity of GSK3 can be down
regulated in response to insulin or IGF-1 through the activation
of the PI3K pathway.
Reduced Cerebral Blood Flow
Neurons depend on blood vessels for their oxygen and
nutrient supplies, and for the removal of carbon dioxide and
other potentially toxic metabolites from the brain’s interstitial
fluid. Recent evidence suggests that vascular dysfunction leads
to neuronal dysfunction and neurodegeneration, and that
it might contribute to the development of proteinaceous
brain and cerebrovascular “storage” disorders (Zlokovic, 2011).
AD is characterized by a decreased regional cerebral blood
flow that could result in decrease brain supply of oxygen,
glucose, and nutrients. Insulin signaling regulates vasodilation
and vasoconstriction (Aulston et al., 2013). IR activation
mediates vasodilation through PI3K→Akt pathway. It stimulates
endothelial nitric oxide synthase (eNOS) resulting in the
production of nitric oxide (NO) and vascular relaxation
(Figure 1A) (Bolotina et al., 1994; Kahn et al., 1997). IR
activation can also mediate vasoconstriction. Activation of
IR can also lead to phosphorylation of the Src homology
containing (Shc) protein, which in turn binds the Growth factor
receptor-bound protein 2 (Grb-2) resulting in the activation
of Son of sevemless (Sos) protein. This complex then activates
the Rat sarcoma (Ras) protein leading to phosphorylation of
Rapidly accelerated fibrosarcoma (Raf) protein kinase that results
in activation of Mitogen-activated protein kinase (MAPK).
Activation of MAPK stimulates release of endothelin-1 (ET-
1), a vasoconstrictor (Figure 1A) (Potenza et al., 2005, 2006;
Formoso et al., 2006). By mediating vascular properties, insulin
signaling plays an important role in glucose and oxygen
availability to the brain (Aulston et al., 2013). In insulin
resistant state, there is a specific impairment in the vasodilatory
PI3K pathway, whereas the Ras/MAPK-dependent pathway is
unaffected (Jiang et al., 1999; Cusi et al., 2000). This results
in decreased NO production and increased production of ET-
1 in humans leading to vasoconstriction (Figure 1B) (Piatti
et al., 1996). NO further plays important role in protecting
blood vessels from endogenous injury by preventing platelet
and leukocyte interactions (Kubes et al., 1991; Sarkar et al.,
1996). Decreased production of NO allows for increased
expression of proinflammatory transcription of the nuclear
factor-κB (NFκB), and production of chemokines and cytokines
(Zeiher et al., 1995). The resultant decrease in nutrient
availability to the brain due to decreased NO production
results in an increase of oxidative stress and reactive oxygen
species (ROS) production and an increased inflammatory
response. Released pro-inflammatory cytokines and macrophage
recruitment instigates the onset of atherosclerosis, ultimately
leading to macrovascular complications (Aulston et al., 2013).
Moreover, insulin can improve dendritic spine density and
rescue spine loss caused by apolipoprotein E 4 (APOE4). APOE4,
a major genetic risk factor for AD, exerts neuropathological
effects through multiple pathways, including impairment of
dendritic spine structure and mitochondrial function. It has been
shown that insulin sensitizers, such as rosiglitazone [peroxisome
proliferator-activated receptor gamma (PPAR-γ)], significantly
increased dendritic spine density and rescued detrimental effects
of APOE4 on dendritic spine (Brodbeck et al., 2008). Thus,
it is suggested that rosiglitazone might improve cognition in
AD patients by increasing dendritic spine density. There is
also evidence that insulin sensitizers modulate mitochondrial
function (Wang et al., 2002). Fuenzalida and co-workers reported
that rosiglitazone treatment in neuronal cells up-regulates Bcl-
2 thereby stabilizing mitochondrial potential and protecting
against apoptosis (Fuenzalida et al., 2007).
Intranasal Insulin Delivery to the Brain
Thus, impaired insulin sensitivity of IR and increased insulin
resistance at brain may contribute to number of pathological
processes that lead to acceleration of AD pathology. Therefore,
restoring insulin to normal levels in the brain by insulin
treatment, as showed in laboratory animals, may provide
therapeutic benefits in AD subjects. Unlike, insulin cannot be
administered orally, since it is degraded in the gastrointestinal
track by various enzymes. Increasing brain insulin levels in
AD patients by intravenous administration has been shown
to acutely improve performance on hippocampus-dependent
memory task (Craft et al., 1996). However, high systemic
doses would be needed to achieve functionally effective insulin
concentrations in the brain, causing strong peripheral side effects
such as hypoglycemia and induction and/or exacerbation of
peripheral insulin resistance (Benedict et al., 2011). Therefore
oral and intravenous route of administration is not viable
in clinical setting. In contrast, intranasal administration is a
promising approach to selectively enhance brain insulin levels
while avoiding adverse side effects (Born et al., 2002). This route
offers a relatively high bioavailability, avoidance of the first-
pass effect and invasive administration. Intranasal administration
of insulin provides rapid delivery of insulin to the central
nervous system via bulk flow via along olfactory and trigeminal
perivascular channels, and slower delivery via olfactory bulb
axonal transports (Thorne and Frey, 2001; Craft et al., 2012).
Clinical studies have shown that intranasally administered
insulin reaches to cerebrospinal fluid (CSF) within 30min
Frontiers in Neuroscience | www.frontiersin.org 7 June 2015 | Volume 9 | Article 204
Bedse et al. Aberrant insulin signaling in Alzheimer’s disease
without substantial uptake into the bloodstream, bypassing the
bloodstream (Born et al., 2002). Moreover, insulin exerts rapid
changes on oscillatory electroencephalogram (EEG) parameters
(Hallschmid et al., 2004). However, such comparable effects
on EEG were not observed to those induced by intravenous
bolus injection of insulin, suggesting that following intranasal
administration, a significant amount of administered insulin dose
reaches to the brain in a functional active state (Hallschmid et al.,
2004). Recently, National Institute of Health (NIH) has selected
intranasal insulin administration as one of the two therapeutic
strategies receiving substantial funding as part of the National
Alzheimer’s Plan in the US (Wadman, 2012). This plan is a
part of the initiative to find a therapeutic treatment to cure AD
by 2025.
Intranasal Insulin Improves Memory in the
Healthy Humans as Well as in the AD
Patients
Enhancing central nervous insulin action has been shown to
improve memory functions in animals as well as in humans (see
Table 2) (Benedict et al., 2011). In a human study, the effects
of 8 weeks of intranasal insulin (4 × 40 IU/d) and placebo
were assessed on hippocampus-dependent declarative memory
in 38 health subjects (Benedict et al., 2004). At the beginning
and end of treatment, in total 30 words were orally presented
to subjects. The subjects were asked to write down all words
they still remembered after 3min (immediate recall session)
and one week later (delayed recall session) after presentation
of words. The subjects treated with the insulin remembered
significantly more words in delayed recall session, but not in
immediate recall session, compared to placebo group. In this
study the improving effect of subchronic intranasal insulin
administration seemed to be specific for hippocampus dependent
declarative memory, without any peripheral side effects. As
far as the increased delayed recall authors pointed out that
the improvement in the insulin-treated group occurred on a
background of a generally decreasing performance. In addition,
authors suggested that it might reflects an influence on encoding
of the words at learning or a direct influence on retrieval,
rather than an effect on the proper consolidation of memory.
The same research group further studied effects of rapid-acting
insulin analog insulin aspart, regular human insulin and placebo
under similar experimental conditions (Benedict et al., 2007).
Authors hypothesized that rapidly absorbed insulin aspart would
show stronger effects on memory functions than regular human
insulin due to the higher efficiency to reach brain. After 8 weeks
of treatment subjects treated with both regular human insulin
and insulin aspart remembered significantly more words than
placebo group. Insulin aspart-treated subjects performed even
better that those treated with regular human insulin (Benedict
et al., 2007).
In a study, gender differences regarding acute effects of
central nervous insulin 160 IU were studied in 32 young healthy
subjects (18 women and 14 men) in hippocampus-dependent
two-dimensional-object location task and working memory task
(digit span) (Benedict et al., 2008). Acute insulin treatment
significantly improved hippocampus-dependent memory and
working memory in women but not in men. The same group of
researchers further showed that these effects were not restricted
only to young women but also for postmenopausal women (Krug
et al., 2010). Based on the encouraging effects of intranasal insulin
that demonstrated improvement of memory without any side
effects in healthy humans, few clinical trial have been carried
out in patients with mild cognitive impairments (MCI) and
AD patients. In a first study, 26 memory-impaired subjects (13
with early AD and 13 with mild MCI) and 35 normal controls
received intranasal insulin (20 or 40 IU) or saline (placebo)
treatments (Reger et al., 2006). Cognition was tested 15min
post-treatment, and blood was acquired at baseline and 45min
after treatment. Intranasal insulin treatment did not change
plasma insulin or glucose levels. Insulin treatment facilitated
recall on two measures of verbal memory in memory-impaired
APOE negative adults. These effects were stronger for memory-
impaired APOE negative subjects than for memory-impaired
APOE positive subjects and normal adults. Unexpectedly,
memory-impaired APOE positive subjects showed poorer recall
following insulin administration on one test of memory. This
study provided further evidence for APOE-related differences
in insulin metabolism. Another study supported the same
observation that intranasal administration improves cognition
in APOE negative patients (Reger et al., 2008a). Recently, it
has been demonstrated that high dose of insulin (40 IU) can
improve visuospatial and verbal working memory in APOE
positive MCI and AD patients (Claxton et al., 2015). High
dose of insulin also improved peripheral insulin resistance
in APOE positive patients. Conversely, high dose of insulin
experienced increased peripheral insulin resistance in APOE
negative patients (Claxton et al., 2015). These findings suggest
that groups with different genetic risks for AD may show
differential dose-response curves following intranasal insulin
administration (Reger et al., 2008a; Rosenbloom et al., 2014).
Further, it is reported that insulin treated subjects retained more
verbal information, improved attention and raised fasting plasma
Aβ40/Aβ42 ratio (Reger et al., 2008b). Another study supported
the notion that the intranasal administration of insulin improves
cognition in patients affected by mild cognitive impairment
or AD (Craft et al., 2012). However, authors did not observe
any changes in the Aβ42 and tau levels in the CSF after
treatment.
Conclusions
The advances in AD research in the last decade have revealed
that AD is linked to insulin signaling deficiency in the brain. This
hypothesis was further strengthen when intracerebroventricular
administration of streptozotocin resulted in AD-like cognitive
impairments, neurodegeneration and insulin resistance (Lester-
Coll et al., 2006; de La Monte, 2014). Insulin/IGF signaling
promotes the trafficking of AβPP-Aβ (Watson et al., 2003) and
also enhances clearance of Aβ by modulating Aβ transporters
and carriers at the BBB (Carro et al., 2002; Ashpole et al.,
2015). Moreover, insulin/IGF negatively controls Aβ intracellular
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TABLE 2 | Intranasal insulin improves memory function.
Subjects Intranasal insulin duration/dose Main result References
Healthy humans 4× 40 IU/day, for 8 weeks Intranasal intake of insulin enhanced long-term declarative memory
and positively affected mood in humans without causing systemic
side effects like hypoglycaemia.
Benedict et al., 2004
Healthy humans 4× 40 IU/day, for 8 weeks; insulin
and rapid-acting insulin analog insulin
aspart
Declarative memory was improved in insulin and insulin aspart
groups compared to placebo group without altering glucose levels.
Insulin aspart treated subjects performed even better that those of
insulin treated group
Benedict et al., 2007
Healthy humans Single dose of regular human insulin
160 IU
Hippocampus-dependent memory and working memory were
improved in women where as men did not benefit from acute insulin
treatment
Benedict et al., 2008;
Krug et al., 2010
MCI and mild AD patients 20 or 40 IU of insulin acute treatment Acute intranasal insulin administration improved verbal memory in
AD and MCI subjects without the APOE- ε4 allele
Reger et al., 2006
MCI and AD patients 10, 20, 40, or 60 IU for 5 days 10, 20, and 40 IU of insulin improved declarative memory only in
APOE-ε4 negative patients
Memory facilitation generally peaked at the 20 IU dose
↑ Aβ42 levels for memory-impaired adults from saline to 10 IU
regardless of APOE-ε4 status
Intranasal insulin did not affect peripheral glucose or insulin levels
Reger et al., 2008a
MCI and AD patients 20 IU BID intranasal insulin treatment
for 21 days
Insulin-treated subjects retained more verbal information and
improved attention and functional status
Insulin treatment raised fasting plasma Aβ40/Aβ42 ratio
Reger et al., 2008b
MCI and mild to moderate
AD patients
20 or 40 IU for 4 months Treatment with 20 IU of insulin improved delayed memory
Both dosages preserved caregiver-rated functional ability and
general cognition
Unchanged Aβ42 and tau levels after insulin treatment
Craft et al., 2012
AD patients with ApoE4
allels
Rapid acting insulin Rapid acting insulin failed to have an acute impact on cognition in
ApoE4 carriers with AD
Rosenbloom et al.,
2014
MCI and mild AD patients 20 or 40 IU of insulin detemir for 21
days
High dose (40 IU) improved visuospatial and verbal working memory
for all participant
High dose improved memory for adults with MCI and AD who were
APOE-ε4 positive patients
APOE-ε4 carriers taking high dose also improved peripheral insulin
resistance
APOE-ε4 negative patients taking high dose experiences increased
peripheral insulin resistance
Claxton et al., 2015
S.D. rats—streptozotocin
induced AD model
5 IU for 6 days Insulin administration significantly reduced the Aβ levels without
altering peripheral glucose levels
Subramanian and
John, 2012
Streptozotocin
induced-rat model of type
2 diabetes
2U insulin intranasally/4 weeks
6.7 U/kg (s.c.)/4 weeks
Decreased Akt activation and increased tau phosphorylation and
GSK-3β activation was found in T2D rat brains.
Intranasal insulin treatment normalized Akt and GSK-3β and reduced
tau phosphorylation in diabetic rats
s.c. insulin had minimal effect of tau phosphorylation and GSK-3β
Yang et al., 2013
3 × Tg-AD mice 1.75 U/7 days Intranasal insulin administration restored insulin signaling, ↑ synaptic
proteins, and ↓ Aβ40 level and microglia activation in the brains of 3
× Tg-AD mice.
Glucose transporters and tau-phosphorylation is unchanged
Chen et al., 2014c
3 × Tg-AD mice 1.75 U/7 days
Propofol 250mg/kg (i.p.)
Insulin treatment attenuated propofol-induced hyperphosphorylation
of tau, promoted brain insulin signaling.
Resulted in down-regulation of several tau protein kinases, including
cyclin-dependent protein kinase 5, calcium/calmodulin-dependent
protein kinase II, and c-JunN-terminal kinase and up-regulation of
protein phosphatase 2A
Chen et al., 2014b
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deposition, tau phosphorylation and degradation by IDE
(Gasparini et al., 2001, 2002). Deregulation of insulin/IGF
signaling increases Aβ deposition, tau phosphorylation, reactive
species and decreases cerebral blood flow (Figure 1) (de La
Monte, 2014). Accumulation of Aβ oligomers further worsen
insulin deficiency by decreasing insulin’s binding affinity to
its receptors, reducing and desensitizing cell surface IRs and
phosphorylating IRS-1 (Figure 1) (Lacor et al., 2007; Zhao et al.,
2008;Ma et al., 2009; Fernandez and Torres-Aleman, 2012; Talbot
et al., 2012). This review proposed intra nasal administration
as potential therapeutics, which has been shown to improve
cognition (Table 2) without any side effects in clinical trials.
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